(Q37281586)

19 August 2017

1 reference

title

Lapatinib and ixabepilone for the treatment of metastatic breast cancer (English)

1 reference

19 August 2017

main subject

metastatic breast cancer

1 reference

1 reference

Patti A Halterman

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

28

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

1255-1266

1 reference

Preoperative chemotherapy treatment of breast cancer--a review

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Management of advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Overcoming treatment challenges in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

The value of label recommendations: how to dose lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Lapatinib-associated toxicity and practical management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Managing treatment side effects in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Lapatinib in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Epothilones in breast cancer: review of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

End points and United States Food and Drug Administration approval of oncology drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.10.1255

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.10.1255

1 reference

19 August 2017

1 reference